Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution

Domenico Ferraioli, Leonardo Peñuela, Anna Garuti, Chiara Carrozzi, Timothee Olivier, Bruno Spina, Sandra Salvi, Simone Ferrero, Jean Christophe Tille, Sana Intidhar Labidi-Galy, Gabriella Cirmena, Alberto Ballestero, Nicolas Chopin, Frederic Beurrier, Isabelle Treilleux, Isabelle Ray-Coquard, Gabriele Zoppoli, Valerio Gaetano Vellone

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalinfixed, paraffinembedded (FFPE) highgrade serous ovarian carcinoma (HGSOC) samples. STUDY DESIGN: We validated a reliable SLFN11 antibody (SLFN11Ab) in IHC choosing between 2 antiSLFN11Abs used for western blot through the development of a SLFN11IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. RESULTS: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression. CONCLUSION: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot antiSLFN11Ab.

Original languageEnglish
Pages (from-to)222-230
Number of pages9
JournalAnalytical and Quantitative Cytopathology and Histopathology
Volume40
Issue number5
Publication statusPublished - Oct 1 2018

Keywords

  • Anti-SLFN11 antibody
  • Histological score
  • Immunohistochemistry
  • Ovarian cancer
  • Ovarian neoplasms
  • Schlafen-11
  • Serous high grade ovarian cancer.
  • SLFN11

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine
  • Cell Biology

Fingerprint Dive into the research topics of 'Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution'. Together they form a unique fingerprint.

  • Cite this

    Ferraioli, D., Peñuela, L., Garuti, A., Carrozzi, C., Olivier, T., Spina, B., Salvi, S., Ferrero, S., Tille, J. C., Labidi-Galy, S. I., Cirmena, G., Ballestero, A., Chopin, N., Beurrier, F., Treilleux, I., Ray-Coquard, I., Zoppoli, G., & Vellone, V. G. (2018). Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution. Analytical and Quantitative Cytopathology and Histopathology, 40(5), 222-230.